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ArterivirusPorcine reproductive and respiratory syndrome virus (PRRSV) is the causative agent of PRRS, which is
characterized by late-term abortions in sows and respiratory disease in young pigs. Using an infectious cDNA
clone of North American PRRSV strain P129, the viral genome was engineered to transcribe an additional
subgenomic RNA initiating between non-structural and structural genes. Two unique restriction sites and a
copy of the transcription regulatory sequence for ORF6 (TRS6) were inserted between ORFs 1b and 2a,
yielding a general purpose expression vector. The enhanced green ﬂuorescent protein (GFP) gene was cloned
between the unique sites such that the inserted gene was transcribed from TRS2 which was located upstream
within ORF1b, while the copy of TRS6 drives ORF2a/b transcription. Upon transfection of cells with this
plasmid, PRRSV infection was initiated and progeny virus “P129-GFP” was obtained. Cells infected with P129-
GFP showed ﬂuorescence and the inserted gene was phenotypically stable for at least 37 serial in vitro
passages. Subsequently, a capsid (C) protein gene was cloned from porcine circovirus type 2 (PCV2)
recovered from an outbreak of porcine multisystemic wasting syndrome (PMWS) and inserted into the
PRRSV infectious clone vector, generating virus “P129-PCV”. To determine the immunogenicity of the
recombinant viruses, pigs were immunized intramuscularly with P129-WT (wild-type), P129-GFP, or P129-
PCV2. By 5 weeks post-infection, speciﬁc antibody responses to GFP and PCV2 capsid were elicited. This is the
ﬁrst report of foreign gene expression using PRRSV from dedicated subgenomic RNAs and demonstrates the
potential use of PRRSV as a vaccine vector for swine pathogens.© 2009 Elsevier Inc. All rights reserved.IntroductionPorcine reproductive and respiratory syndrome (PRRS) is an
emerged and re-emerging disease in pigs. The disease was ﬁrst
recognized in Germany and the US almost simultaneously in the late
1980s and has since spread globally to most pork producing countries
(Keffaber,1989; Benﬁeld et al.,1992; Albina,1997). PRRS is characterized
by abortions and mummiﬁed fetuses in sows, and respiratory distress
with poor growth in young pigs. The disease is mild in gilts and boars,
but the virus (PRRSV) persists in semen and thus can be transmitted
widely by artiﬁcial insemination. Since its emergence, PRRS has become
one of the most economically important diseases in the swine industry.
Modiﬁed-live vaccines are available, but safety and limited efﬁcacy arel Disease Control and Breeding,
dong, China.
ll rights reserved.ongoing concerns. No speciﬁc treatment is available for PRRS, and thus
the economic losses are enormous. Numerous isolates of PRRSV
representing many geographical regions have been sequenced, revea-
ling the existence of two distinct genotypes of PRRSV: European (type I)
andNorthAmerican (type II). The two genotypes share overall sequence
identity of 63% and differ antigenically as well as genetically (Nelson
et al., 1993; Meng et al., 1995; Wootton et al., 2000).
PRRS virus is an enveloped, single-stranded, positive-sense RNAvirus
belonging to the family Arteriviridae and along with the Coronaviridae
family, forms the orderNidovirales. The PRRSV genome is approximately
15 kb in size and includes the 5′ cap structure and 3′ polyadenylated tail
(Sagripanti et al., 1986; Wootton et al., 2000). The genome consists of
ninegenes: open reading frames (ORFs) 1a,1b, 2a, 2b, 3, 4, 5, 6, and7. The
5′ three-quarters of the genome consists of two slightly overlapping
ORFs,1a and 1b, and they are translated directly from the genome-sense
RNA. ORF1b is expressed as a fusion protein with ORF1a by a frame-
shifting mechanism, and the ORF1a and ORFla/b proteins are auto-
cleaved by viral proteases into at least 13 cleavage products that are the
92 Y. Pei et al. / Virology 389 (2009) 91–99non-structural proteins Nsp1α, Nsp1β, and Nsp2 through Nsp12. The
Nsps are thought to be involved in genome replication and subgenome
transcription (van Dinten et al., 1999; van Marle et al., 1999). The viral
structural proteins are encoded by ORFs 2a, 2b, and 3 through 7 which
are located downstream of ORFs 1a and 1b. These genes are expressed as
a 3′-coterminal nested set of subgenomic (sg) RNAs (de Vries et al.,
1990). The 5′ untranslated leader sequences of the sgRNAs are derived
from the 5′ end of the viral genome and fused to the body segments of
the sgRNAs at conserved hexanucleotide motifs [5′UCAAC(U/C)3′]
located immediate upstream of every transcription unit (de Vries et al.,
1990; den Boon et al., 1996). The conserved hexanucleotide motif and
poorly conserved ﬂanking sequences form secondary structures in the
sgRNAs thatmakeup the transcriptional regulatory sequences (TRS) that
are necessary for sgRNA formation (Pasternak et al., 2000). With theFig. 1. Genomic organization of P129-WT, P129-GFP, and P129-PCV2. (A) Genomic organizati
“wild-type” P129 strain of PRRSV (P129-WT). The boxed sequence indicates the core hexanuc
the GP2 protein (ORF2a), and the E protein (ORF2b). The initiation codons are indicated in b
sequence positions. Stars indicate translation stops. (B) P129-GFP. Unique Aﬂ II and Mlu I sit
ORF2a, creating expression vector pCMV-S-P129-1bMCS2. The GFP gene was ampliﬁed by P
capsid gene was ampliﬁed by PCR and cloned between the Aﬂ II and Mlu I restriction sites.exception of sgRNA7, sgRNAs are structurally polycistronic but, with the
exception of sgRNA2a/b, functionally monocistronic as only the 5′ most
proximal gene of each sgRNA is translated. ORFs 2a, 2b, and 3 through 7
code for GP2 (glycoprotein 2), E (envelope), GP3, GP4, GP5, M
(membrane) and N (nucleocapsid) proteins, respectively, and they
make up virion particles (Meulenberg et al., 1995).
The recent development of infectious clones for PRRSV has allowed
speciﬁc alterations of viral genomes andgenerationofmutant viruses (Yoo
et al., 2004). However,manipulation of arterivirus genomes is complicated
by the condensed organization of the viral genome. In the case of the
European genotype of PRRSV, each gene overlaps slightly except for ORFs
1b and 2a (Meulenberg et al., 1993), although the overlap of genes seems
less important for virus replication and growth for equine arteritis virus
(de Vries et al., 2000). For the North American genotype, structural geneson and sequence of the region surrounding the ORF1b/ORF2 junction of the unmodiﬁed
leotide of TRS2. Amino acids indicate translated sequences of polyprotein 1a/b (ORF 1b),
old, and the E protein sequence is italicized. Numbers in parenthesis indicate genomic
es and a copy of TRS6 were introduced into the non-coding region between ORF1b and
CR and inserted between the Aﬂ II and Mlu I restriction sites. (C) P129-PCV2. The PCV2
93Y. Pei et al. / Virology 389 (2009) 91–99also overlap with the exceptions of ORFs 1b and 2a, and ORFs 4 and 5
(Nelsen et al., 1999; den Boon et al., 1991; Snijder andMeulenberg, 1998).
Thus, the entire genomeof theNorthAmerican type PRRSVpossesses only
4 short non-coding regions: 191 nucleotides of 5′ untranslated region
(UTR), 1 nucleotide between ORF1b and ORF2a, 10 nucleotides between
ORF4 and ORF5, and 151 nucleotides of 3′ UTR upstream of the
polyadenylation tail. The 5′ and 3′ UTRs contain genome replication and
transcription signals, and therefore offer limited sites for gene insertion
andmanipulation. Thepresence of overlapping genes hampersmutational
analysis of theN- andC-termini of the structural proteins andalsomakes it
difﬁcult to insert heterologous genes into the viral genome. In the present
study, we used a genomic cDNA clone of PRRSV (Lee et al., 2005) to
generateavector for foreigngeneexpression fromadedicated subgenomic
transcription unit inserted in the region between the structural and non-
structural genes. The vector was used to express GFP in vitro and in vivo.
The inserted genewas tolerated by the virus, stable for at least 37 passages
in cell culture, and induced antibodies to GFP in young pigs.
Using this approach, we also generated a recombinant PRRSV
expressing the capsid protein gene of porcine circovirus type 2 (PCV2).
PCV2 is a small DNA virus in the Circoviridae family, with a genome ofFig. 2. (A) Restriction patterns of P129-WT (lane 1), P129-GFP (lane 2), and P129-PCV2 (la
10,779 bp are expected from all three clones. The fourth fragment varies in size depending
P129-WT fragment (2787 bp, lane 1), the GFP-containing fragment from P129-GFP is 766 bp
754 bp larger (3541 bp, lane 3). (B–E) Recovery of recombinant PRRSV foci from full-length g
was extracted from P129-GFP virus and digested with DNase I prior to reverse transcription.
speciﬁc PCR primers P129-7F and P129-7R (lane 1) or primers P129-1bF and P129-2aR that s
ampliﬁed the ORF 7 fragment (534 bp) from both P129-WT (lane 3) and P129-GFP (lane 4). U
P129-WT (lane 5) was ampliﬁed from P129-GFP. (G) Integration of the PCV2 C gene in PRRS
ampliﬁed using primers P129-1bF and P129-2aR. Compared to P129-WT (lane 9) a product t
primers PCV2-F and PCV2-R, the expected 497 bp product was generated from P129-PCV2 (la
P129-4R, the expected 567 bp product was ampliﬁed from both P129-PCV2 and P129-WT (only 1.76 kb. PCV2 ORF1 is essential for viral DNA replication
(Mankertz et al., 1998; Fenaux et al., 2000), while ORF2 encodes the
capsid protein containing type-speciﬁc epitopes that are believed to be
important for virus neutralization (Nawagitgul et al., 2000; Fenaux
et al., 2004). Accumulating evidence suggests a major role for PCV2 in
postweaning multisystemic wasting syndrome (PMWS) and porcine
dermatitis and nephropathy syndrome (PDNS) (Hasslung et al., 2005).
These syndromes cause serious economic impacts in the swine
industry today (Chae 2005). We showed the recombinant PRRSV
P129-PCV2 induced an anti-PCV2 antibody response in immunized
pigs in the presence of maternal antibodies to PCV2. Our vector
construction may be applicable not only for PRRSV, but also for other
members of the families Arteriviridae and Coronaviridae.
Results
Development of PRRSV as an expression vector for GFP
To explore the possibility of developing PRRSV as a gene expression
vector, the GFP gene was inserted between the stop codon of ORF1bne 3) genomic clones generated by Sma I digestion. Fragments of 590 bp, 4736 bp and
on the gene inserted at the non-structural and structural gene junction. Relative to the
larger (3553 bp, lane 2) and the PCV2 capsid-containing fragment from P129-PCV2 is
enomic clones. (F) Integration of the GFP gene in P129-GFP viral genome. Genomic RNA
Without reverse transcription, no products were ampliﬁed from P129-GFP using ORF7-
pan the insertion site (lane 2). With reverse transcription, primers P129-7F and P129-7R
sing P129-1bF and P129-2aR, a product of 766 bp larger (lane 6) than the product from
V. Genomic RNA from P129-WT (lanes 9, 10, 12) and P129-PCV2 (lanes 7, 8, and 11) was
hat is 754 bp larger was ampliﬁed from P129-PCV2 (lane 7). Using PCV2 C gene speciﬁc
ne 8) but not from P129-WT (lane 10). Using PRRSV ORF4-speciﬁc primers P129-4F and
lanes 11 and 12, respectively).
Table 1
Stability of GFP expression in P129-GFP virus.
Virus Titer (PFU/ml) GFP expressing plaques
Passage 3 8.3×10e6 20 positive/20 plaques
Passage 37 2.4×10e7 20 positive/20 plaques
94 Y. Pei et al. / Virology 389 (2009) 91–99and the start codon of ORF2a (Fig. 1A). This non-coding region is
extremely short, comprising only one adenosine nucleotide. The TRS
associated with ORFs 2a and 2b (TRS2; TGAACC) is positioned 26
nucleotides upstream from the start of ORF2a and is embedded in
ORF1b. Upon insertion of GFP to the region, TRS2 will drive
transcription of the GFP gene instead of ORFs 2a and 2b. Thus, a
synthetic TRS (TTAACC) with ﬂanking sequences derived from TRS6
was introduced 22 nucleotides downstream of GFP and 17 nucleotides
upstream from the ORF2a start (Fig. 1B). TRS6 was chosen because
RNA secondary structure suggested that it was shorter than other
PRRSV TRS elements and because the distance between the copy of
TRS6 driving ORF2a/b and the authentic TRS6 ensured that potential
intramolecular homologous RNA recombination would result in a
non-viable (ORF2-5 deleted) virus. The PRRSV genomic clone
containing GFP was designated P129-GFP, and the insertion was
conﬁrmed by restriction patterns (Fig. 2A, lane 2) and sequencing.
MARC-145 cells were transfected with P129-GFP and the production
of virus was monitored daily for development of cytopathic effect
(CPE) (Figs. 2B, C, D). CPE was observed 4 days post-transfection and
the development of CPE was one day slower than for P129-WT. After
three consecutive passages, P129-GFP virus was re-examined for GFP
sequence integration in the viral genome (Fig. 2F). While ORF7
ampliﬁcation products were identical in size for P129-WT (lane 3) and
P129-GFP (lane 4),1bF and 2aR primers produced a larger size product
from P129-GFP (lane 6) than from P129-WT (lane 5). The larger
product was the expected size for correct insertion of GFP gene intoFig. 3. Expression of GFP or PCV2 capsid protein by P129-GFP and P129-PCV2 inMARC-145 ce
passage 37; (C) uninfected cells; (D) P129-PCV2 passage 3 ﬁxed and stained with PCV2-spec
cells ﬁxed and co-stained with PCV2-speciﬁc antibody conjugated with FITC (E) or GP4 prothe viral genome. Replication of P129-GFP was slightly slower than
that of P129-WT at passages 1 to 3. However, plaques were
comparable in size and morphology for P129-WT and P129-GFP, and
the titers at passage 3 were 5×105 plaque forming units (PFU)/ml
and 1×105 PFU/ml, respectively. Fluorescence was evident in P129-
GFP-infected cells (Fig. 3A), demonstrating the expression of GFP
during infection. To examine the genetic stability of recombinant
PRRSV, P129-GFP was passaged 37 times in MARC-145 cells and GFP
expression was monitored by ﬂuorescence microscopy. Individual
plaques of 20 formed by P129-GFP were randomly chosen and
examined for ﬂuorescence. The selected plaques were all positive for
ﬂuorescence (Table 1), and sequencing of the viral RNA conﬁrmed
stability of the insert (data not shown). This data showed the genetic
stability of P129-GFP after serial passages in cell culture and the stable
expression of GFP. It also demonstrates that the region between ORF1b
and ORF2a is a suitable site for foreign gene insertion for PRRSV. This
was the ﬁrst demonstration of the use of a nidovirus as an expression
vector wherein the foreign gene is inserted in the region between the
non-structural and structural protein coding sequences.lls. (A) Live cells infectedwith P129-GFP passage 3; (B) live cells infected with P129-GFP
iﬁc antibody conjugated with FITC at 48 h post-infection; (E and F) P129-PCV2 infected
tein-speciﬁc monoclonal antibody 169 (F).
Fig. 4. Co-expression of the PRRSV N protein (green) and the PCV2 capsid protein (red) during infection of P129-PCV2. MARC-145 cells were infected with P129-PCV2 and stained
24 h post-infectionwith PRRSV N-speciﬁc MAb SDOW-17 (A and B) or PCV2-speciﬁc pig serum (C and D). Arrows indicate the PRRSV N protein in the nucleolus (panel A) in addition
to the cytoplasm and the PCV2 capsid protein in the nucleus and nucleolus (panel C). Panel E shows the merge of A and C. Panel F shows the merge of B and D.
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PCV2 is associated with porcine multisystemic wasting disease
(PMWS, now termed PCVAD [PCV-associated disease]) and porcine
dermatitis and nephropathy syndrome (PDNS). PCV2 is transmitted by
the oro-nasal route and shed in the bronchial secretions and feces, thus
the transmission route is similar to that of PRRSV. The capsid (C) protein
is the major antigen able to elicit protective immunity against PCV2.
Thus, using the PRRSV vector system described above, an additional
recombinant PRRSVwas constructed to carry the PCV2 C gene. A 702 bp
C gene was cloned by PCR from a lung tissue positive for PCV2.
Sequencing of the C gene showed 99–100% amino acid identity to
published sequences available in the GenBank database. The P129-PCV2
clone was constructed by inserting the C gene into PRRSV in the same
wayas theGFP gene insertion for P129-GFP (Fig.1C). The insertionof the
C gene was conﬁrmed by restriction digestion pattern (Fig. 2A, lane 3)
and sequencing. The P129-PCV2 recombinant virus was recovered from
MARC-145 cells by transfection (Fig. 2E), and the insertion of the C geneTable 2
PCR primers and their genomic positions.
Name Sequence (5′–3′)a
PCV2-F cacggatattgtagtcctggt
PCV2-R ccgcaccttcggatatactgtc
PCV2-orf2F gatgcttaagatgacgtatccaaggtggcg
PCV2-orf2R gtacacgcgtcattaagggttaagtcccccc
P129-F1F aacagaagagttgtcgggtccac
P129-F1R gctttcacgcgtccccacttaagttcaattcaggcctaaagttggttca
P129-F2F gcgacgcgtgttccgtggcaacccctttaaccagagtttcagcggaaga
atgaaatggggtctatacaaagcctcttcgaca
P129-F2R aacagaacggcacgatacaccacaaa
P129-7F tcatccgattgcggcaaatg
P129-7R agaatgccagcccatca
P129-4F gtttcacctagaatggctg
P129-4R ccccaacatacttgaacattc
P129-1bF ggtgaggactgggaggattac
P129-2aR cagtacgtagcattggaacc
a Restriction sites are underlined. TRS6 and surrounding sequences are indicated in bold.
b Genomic positions for PCV2 primers were based on GenBank accession AF027217. Genoin the viral genomewas conﬁrmed by RT-PCR of the viral RNA (Fig. 2G).
The titer of passage 3 virus was 2×105 PFU/ml and the plaque
morphology was indistinguishable from P129-WT. Infection of cells
with P129-PCV2 and staining with PCV2-speciﬁc antibody produced
distinct ﬂuorescence (Fig. 3E), which shows the expression of the C
protein by P129-PCV2. The capsid protein of PCV2 is arginine-rich and
normally shuttles into the nucleus during PCV2 replication (Liu et al.,
2001), and similarly, the PRRSV N has also been shown to localize in the
nucleus and nucleolus (Lee et al., 2006; Pei et al., 2008). Thus, in cells
infectedwith P129-PCV2, the synthesis of legitimate PCV2 capsid should
be evident by the translocation of capsid into the nucleus. Thus, the C
protein expression by P129-PCV2was conﬁrmed by co-stainingof virus-
infected cells with PRRSV N protein-speciﬁc antibody and PCV2-speciﬁc
antiserum (Fig. 4). While the PRRSV N protein was found in the both
cytoplasm and the nucleolus as usual (panel A), the PCV2 capsid protein
was speciﬁcally localized to the nucleus and nucleolus (panel C) in the
same cell, clearly demonstrating the expression of PCV2 capsid protein
by the recombinant PRRSV P129-PCV2.Genomic positionb Purpose
1093–1114 PCV2 PCR test
1565–1586 PCV2 PCR test
1715–1734 PCV2 ORF2 ampliﬁcation
1031–1050 PCV2 ORF2 ampliﬁcation
11,699–11,721 P129 11,783–12,055, ampliﬁcation
12,031–12,055 Introduction of Aﬂ II and Mlu I
12,056–12,089 P129 12,056–12,697, ampliﬁcation and
introduction of Mlu I and TRS6
13,819–13,844 P129 12,056–12,679, ampliﬁcation
14,724–14,743 P129 ORF7 ampliﬁcation
15,242–15,258 P129 ORF7 ampliﬁcation
13,213–13,231 ORF4 ampliﬁcation
13,750–13,770 ORF4 ampliﬁcation
11,921–11,941 ORF1b–ORF2a, region ampliﬁcation
12,758–12,777 ORF1b–ORF2a, region ampliﬁcation
mic position for P129 primers were based on GenBank accession AF494042.
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To determine antibody responses to GFP and the PCV2 capsid
protein, pigs were immunized with the recombinant PRRS viruses.
Fifteen PRRSV-free pigs at 4 weeks of age were randomly allotted to 3
groups of 5 pigs each. Animals were immunized twice on days 0 and
21 by intramuscular injection of 5×105 PFU per animal with either
P129-WT, P129-GFP, or P129-PCV2. Following inoculation, the animalsFig. 5. ELISA showing induction of speciﬁc antibodies in sera from pigs inoculated with
P129-GFP, P129-PCV2, or P129-WT viruses. (A) antibodies to PRRSV N protein; (B)
antibodies to GFP; (C) antibodies to PCV2 C protein.
Fig. 6. Western blots showing induction of speciﬁc antibodies in sera from pigs
inoculated with P129-GFP, P129-PCV2, or P129-WT at day 0 or day 35 post-inoculation.
Blots contain GFP protein (A) or PCV2 virions (B). Arrows indicate positions of GFP and
PCV2 capsid protein. C denotes positive control (anti-GFP monoclonal antibody). M
indicatesmolecular weightmarkers. The virus used to infect pigs that contributed to the
serum pools is indicated above each lane.were maintained for 5 weeks for clinical observation and serum
collection. Clinical signs of PRRSwereminimal and comparable in all 3
groups (data not shown). Mild clinical signs were not unexpected,
since the infectious cDNA clone used in these studies was not
attenuated. Tonsil samples were collected at necropsy on day 35 and
assessed by RT-PCR for the presence of PRRSV ORF7 using primers
P129-7F and P129-7R (Table 2) as well as the GFP and PCV2 capsid
inserts using primers P129-1bF and P129-2aR. All 15 pigs were
positive for ORF7, indicating infection and persistence of PRRSV in the
tonsils. PCR products from the ORF1b/ORF2a junction were not
detected in these tonsil samples, possibly due to the much lower
molar ratio of ORF1b-containing RNA template relative to ORF7-
containing RNA in infected cells. Alternatively, it is possible that the
GFP and PCV2 capsid genes might have been unstable in vivo and lost
in the inoculated pigs over time.
To examine antibody responses in these pigs, ELISAs were
conducted for PRRSV, GFP, and PCV2 C protein. All pigs produced
good levels of antibodies to PRRSV (Fig. 5A), and the antibody titers
were comparable among groups. P129-GFP elicited speciﬁc antibodies
to GFP, whereas pigs immunized with P129-PCV2 or P129-WT were
negative for GFP (Fig. 5B). The GFP antibodies increased following ﬁrst
immunization, and the second immunization at day 21 boosted the
antibody response somewhat (Fig. 5B). Similarly, antibodies for PCV2
C protein were detected in pigs immunized with P129-PCV2 (Fig. 5C).
In these pigs, however, PCV2 antibodies were detected at day 0 in all 3
treatment groups and tended to wane over time. These antibodies
likely represent maternal antibodies taken up in colostrum shortly
after farrowing at the farm of origin and prior to experimental
infection. However, an increase in anti-PCV2 antibodies was observed
at 28 days in the P129-PCV2 group only (Fig. 5C) due to boosting
effects from the second immunization at day 21. In contrast, anti-PCV2
antibodies in the other two treatment groups waned gradually from
day 0 until at least until day 35.
To further determine the speciﬁc antibody responses to GFP and
the PCV2 C protein, Western blots were conducted using sera from
these pigs. Serum from the P129-GFP group was reactive with GFP
(Fig. 6A), consistent with the ELISA data (Fig. 5B). Similarly, serum
from the P129-PCV2 group showed a strong reaction with C pro-
tein (Fig. 6B). Weaker reactions were observed using sera from the
P129-WT and P129-GFP groups, consistent with the presence of
maternal antibodies.
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The primary target cell of PRRSV is the alveolar macrophage, and
pigs are the only animal species known to be susceptible to PRRSV
infection. Therefore, development of PRRSV as a vaccine vector would
be useful for the delivery of porcine pathogen genes to the respiratory
tract of the pig. Arterivirus genomes are organized in a complex way.
Most genes overlap one another in different reading frames, making it
difﬁcult to engineer the genome for foreign gene insertion. An early
approach involved engineering the 3′ terminal region of the N gene
(Groot Bramel-Verheije et al., 2000). Modiﬁcation of the 3′ terminal
sequence of N gene was possible and caused only minimal effects on
virus replication and growth. However, no more than 7 amino acids
were inserted. More recently, Nsp2, a large product of proteolytic
cleavage of the ORF1a and ORF1a/b polyproteins, was found to be
remarkably heterogeneous in sequence, with several hypervariable
regions. Therefore, the GFP gene was inserted in-frame into or
between the hypervariable regions to create nsp2-GFP fusion proteins
(Fang et al., 2006; Kim et al., 2007). This approach was successful and
allowed for the production of recombinant viruses. However, in all
cases the inserted GFP gene was not phenotypically stable and lost
green ﬂuorescence after several passages in cell culture (Fang et al.,
2006; Kim et al., 2007; Han et al., 2007). In the present study, we
inserted GFP and the PCV2 capsid genes into the short region
separating the non-structural protein genes from the structural
protein genes. In contrast to the nsp2-GFP fusion proteins described
above, we expressed GFP as a separate transcription unit resulting in
an additional sgRNA. This approach has the advantage of eliminating
the need to alter the coding sequence of a viral gene, and also
minimizes effects on expression and post-translational modiﬁcation
of viral gene products. As a result, our recombinant virus was stable
for at least 37 cell culture passages without loss of the gene or the
green ﬂuorescent phenotype.
PRRSV is known to induce immune suppressive effects in pigs
(Charerntantanakul et al., 2006) and can persist up to 6 months in
infected pigs (Wills et al., 1997). For these reasons, co-infection of
PRRSV with other pathogen such as PCV2 can result in much more
severe clinical outcome than either agent alone (Harms et al., 2001;
Kim et al., 2003). Therefore, a dual-purpose vaccine capable of
protecting pigs against both PRRS and PCV2 would be advantageous.
Our study demonstrates the potential of PRRSV as a viral vaccine
vector.
Prior to the purchase of animals for infection studies using P129-
PCV2, all pigs were screened for PCV2 by PCR. PCR is the gold standard
for detection of PCV2, whereas antibody screening is not routinely
conducted in diagnostic laboratories due to cross-reactivity between
PCV2 and PCV1 which is ubiquitous and widely distributed in the ﬁeld
(Magar et al., 2000). Although all pigs entering the present study
tested negative for the presence of PCV2 by PCR, antibodies were
detected in sera collected on day 0. These antibodies were most likely
of maternal origin, since they decreased in concentration over the
duration of the experiment in pigs receiving P129-WT or P129-GFP.
Serological studies show that maternal antibodies for PCV2 decay
during the ﬁrst 2 months of life (Rodríguez et al., 2002; Larochelle et
al., 2003). Western blots and ELISA gave comparable results in this
regard. In the current study, antibodies to PCV2 only increased after
day 21 of the study and did so only in pigs receiving P129-PCV2,
suggesting that the increases were most likely speciﬁc responses to
P129-PCV2 vaccination. At the termination of the study (day 35 post-
infection), tonsil samples in all 3 groups were positive for the PRRSV N
gene by RT-PCR. The presence of the inserted GFP and PCV2 genes in
these same samples could not be conﬁrmed using primers ﬂanking
the region of the gene insertion. No products were ampliﬁed, even
from pigs infected with the P129-WT virus. Failure to amplify the
ORF1b/ORF2a junction is likely the result of template RNA concentra-
tions below the level of detection of the PCR assay, and is consistentwith the observation that the copy number of ORF1b (present only on
genomic RNA) is much lower than the copy number of ORF7 (present
on all sgRNAs as well as genomic RNA).
In conclusion, a PRRSV gene expression vector was generated,
capable of expressing a foreign gene from an additional transcription
unit located in the region between the non-structural and structural
genes of the virus. The recombinant PRRSVs expressing the GFP or
PCV2 capsid genes were generated and shown to replicate well in cell
culture. The addition of 766 nt (GFP) or 754 nt (PCV2 capsid) of
foreign genetic material, representing approximately 5% of the PRRSV
genome, was tolerated with no evidence of compensatory deletions or
rearrangements elsewhere in the genome. Pigs inoculated with these
recombinant PRRSVs produced foreign gene speciﬁc antibodies. Our
study demonstrates the potential of PRRSV to function as a vector for
development of multivalent vaccines against swine diseases.
Materials and methods
Cells and viruses
MARC-145 African green monkey kidney cells (Kim et al., 1993)
were maintained as previously described (Lee et al., 2003). Dulac
porcine kidney cells, kindly provided by L. Babiuk (Vaccine and
Infectious Disease Organization, SK, Canada), were grown in Modiﬁed
Eagle's Medium (MEM) supplemented with 5% fetal bovine serum
(FBS; Gibco BRL), penicillin (100 U/ml), and streptomycin (50 μg/ml).
Cells were maintained at 37 °C with 5% CO2. Stocks of recombinant
viruses derived from infectious clones were prepared by passaging
three times on MARC-145 cells. Titers of PRRSV were determined by
standard plaque assays onMARC-145 cells using 6-well plates (35mm
diameter) in duplicate. Plaques were stained with 0.01% neutral red.
For isolation of PCV2, lung tissues were obtained from a PCR-positive
pig (Ontario 18099) submitted to Animal Health Laboratory of the
University of Guelph (Guelph, ON, Canada). The tissues were
homogenized in PBS and the ﬁltrate was used to infect Dulac cells.
At 3 days post-infection, cells were stained using a porcine circovirus
hyperimmune serum (VMRD, Pullman,WA, USA) to conﬁrm infection.
On day 4 post-infection, cells were harvested and freeze–thawed
three times. Cell debris was removed by centrifugation at 5000 ×g,
and the supernatant was stored at −80 °C until use.
Construction of a PRRSV expression vector and recombinant PRRSVs
For construction of the PRRSV expression vector, the regions
ﬂanking the ORF1b/ORF2a junction were ampliﬁed by PCR using the
shuttle plasmid p2-7D4 (containing genomic positions 11,504 to
15,395) as template. Two DNA products corresponding to positions
11,783 to 12,055 and 12,056 to 12,697 were ampliﬁed. The primer set
P129F1-F (containing an Eco 47III site) and P129F1-R (containing Aﬂ II
and Mlu I sites) was used for the upstream product (Table 2). The
primers set P129F2-F (containing Mlu I site and TRS6) and P129F2-R
(containing a Bsr GI site) was used to amplify the downstream
product (Table 2). The two ﬂanking products were digested with Eco
47III–Mlu I andMlu I–Bsr GI, respectively, and included in a three-way
ligation with Eco 47III–Bsr GI-digested full-length genomic cDNA
clone pCMV-S-P129 (Lee et al., 2003). The resulting construct pCMV-
S-P129-1bMCS2 contained a complete PRRSV genomewith unique Aﬂ
II and Mlu I sites and a copy of TRS6 inserted between ORF1b and
ORF2a. Transfection of MARC-145 cells with this construct produced
viable virus that replicated normally (data not shown).
For insertion of foreign genes, pCMV-S-P129-1bMCS2was digested
with Aﬂ II–Mlu I and ligated to either the GFP gene or the PCV2 capsid
gene into which Aﬂ II and Mlu I sites were introduced during PCR
(Fig. 1). Recombinant genomic clones were screened by Sma I
digestion (Fig. 2), and selected clones were sequenced to conﬁrm
the presence of insertions. The PCV2 capsid protein gene was cloned
98 Y. Pei et al. / Virology 389 (2009) 91–99from lung tissues of a PCV2 positive pig submitted to the University of
Guelph Animal Health Laboratory. Total DNA was isolated using
DNAzol (Invitrogen), and the PCV2 capsid gene was ampliﬁed using
the forward (PCVORF2-F) and reverse (PCVORF2-R) primers (Table 2).
The PCR product was cloned into pGEM-Teasy (Invitrogen) and
sequenced. DNA manipulation and cloning were performed according
to standard procedures (Sambrook and Russell, 2001).
Production of virus from infectious clones
MARC-145 cells were seeded in 35mm diameter dishes and grown
to 70% conﬂuency. Cells were transfected for 24 h with 2 μg of the full-
length clone using Lipofectin (Invitrogen). Transfected cells were
incubated at 37 °C in DMEM supplemented with 8% FBS. The culture
supernatants were harvested at 5 days post-transfection and desig-
nated ‘passage-1’. The passage-1 virus was used to inoculate fresh
MARC-145 cells, and the 5-day harvest was designated ‘passage-2’.
The ‘passage-3’ virus was prepared in the same way as for passage-2.
Each passage virus was aliquoted and stored at −80 °C until use.
Immunoﬂuorescence
MARC-145 cells were grown overnight to 70% conﬂuency on
microscope coverslips placed in 35 mm diameter dishes. Cells were
infectedwith PRRSV at amultiplicity of infection (MOI) of 0.1 for 1 h at
37 °C and incubated. At 48 h post-infection, cells were washed twice
with PBS and ﬁxed with cold methanol for 10 min at−20 °C, followed
by incubation with 1% bovine serum albumin in PBS for 30 min at
room temperature. For dual staining, cells were incubated with GP4-
speciﬁc MAb 169 (E. Nelson, South Dakota State University, Brookings,
SD) and porcine anti-PCV2 polyclonal antiserum (VMRD, Pullman,
WA) for 2 h. After washing 5 times in PBS, cells were incubated for 1 h
with FITC-conjugated goat anti-mouse IgG (H+L) or Texas red-
conjugated goat anti-swine IgG (H+L) secondary antibody (Mole-
cular Probes). The coverslips were washed 5 times in PBS and
mounted on microscope slides in mounting buffer (60% glycerol and
0.1% sodium azide in PBS). Staining was visualized using a ﬂuorescent
microscope (model AX70, Olympus). For cells infected with P129-GFP
virus, ﬂuorescence was observed directly without use of other
ﬂuorescent reagents. Direct immunoﬂuorescence was conducted
using FITC-conjugated anti-PCV2 polyclonal antiserum (VMRD).
RT-PCR of ORF4, ORF7, and ORF1b/2 junction region
Viral RNA was extracted from supernatants of infected cells using
the QiaAmp viral RNA mini-kit (Qiagen). To remove any possible
contamination of DNA in the RNA preparations, samples were treated
with DNase I (Promega). For total RNA from tissues, approximately
50mg of tonsil sampleswere extracted using Trizol (Invitrogen). First-
strand cDNA synthesis was performed using Moloney murine
leukemia virus (M-MLV) reverse transcriptase (Invitrogen) using re-
verse primers P129N-R, P129ORF4-R, and P129ORF2a-R (Table 2). The
ORF7 (primers P129N-F and P129N-R), ORF4 (primers P129ORF4-F
and P129ORF4-R), and ORF1b-ORF2 (primers P129ORF1b-F and
P129ORF2a-R) regions were ampliﬁed using Taq DNA polymerase
(Invitrogen) under the following conditions: initial denaturation at
94 °C for 5min, 35 cycles of denaturation at 94 °C for 30 s, annealing at
56 °C for 30 s, and extension at 72 °C for 2 min, followed by a ﬁnal
extension at 72 °C for 10 min. PCR products were analyzed by 1%
agarose gel electrophoresis and puriﬁed using a PCR puriﬁcation kit
(Qiagen) prior to sequencing.
Western blot
PCV2 virions and GFP (Sigma) were resolved by 12% SDS-PAGE and
transferred onto nitrocellulose membranes (BioRad). The membraneswere blocked with 1% BSA in TBS (10 mM Tris–HCl [pH 8.0], 150 mM
NaCl) overnight at 4 °C. The blots were incubated with pooled pig
serum from day 0 or day 35 post-inoculation at a dilution of 1:100, or
anti-GFP monoclonal antibody at a dilution of 1:1000 for 1 h and
washed three times with TBS containing 0.05% Tween 20 (TBST). The
blots were then incubated with a solution of alkaline phosphatase-
conjugated goat anti-swine IgG (H+L) (Kirkegaard-Perry Lab [KPL],
Gaithersburg, Maryland) at a dilution of 1:5000 in 1% BSA-TBS for
30 min and washed three times with TBST. Finally, the blot was
incubated with BCIP and NBT staining solution (BioRad) according to
the manufacturer's instructions.
Preparation of virus inoculum and experimental infection of pigs
The passage 4 virus was used for infection studies in pigs. Cells
were infected with passage 3 viruses of P129-WT, P129-GFP, or P129-
PCV2 at 0.1 MOI for 4 days. When extensive CPE developed, culture
supernatants were harvested and cell debris was removed by a low-
speed centrifugation for 10 min at 1350 ×g. Virus in the supernatant
was then concentrated by a high-speed centrifugation for 90 min in a
JA-14 rotor (Beckman) at 30,000 ×g at 4 °C. The pellet was
resuspended overnight in one tenth of the original volume at 4 °C.
Recovery of infectivity of the concentrates was determined by plaque
assay on MARC-145 cells, and the virus stock was stored at −80 °C
until use. For infection of pigs,15 York-Landracemixed breed piglets at
5 weeks of agewere obtained from a high security swine herd. All pigs
tested negative for serum antibodies to PRRSV and Mycoplasma
hyopneumoniae by ELISA prior to admission to the study. Infection
with PCV2 was previously documented in ﬁnishing pigs in the source
herd but not in nursery pigs. All pigs in this study tested PCR-negative
for PCV2 in serum (Animal Health Laboratory, University of Guelph)
on admission to the study. Pigs were housed in the animal isolation
facilities of the OntarioMinistry of Agriculture and Food, located at the
Ontario Veterinary College, University of Guelph (Guelph, Ontario,
Canada). Animals were randomly allotted to three groups, ﬁve piglets
per group, and animals within the same group were housed in the
same room. All pigs were acclimated for 7 days prior to inoculation.
Throughout the study, pigs were fed an age-appropriate non-
medicated diet and provided with water ad libitum. On day 0 of the
study, the P129-WT, P129-GFP and P129-PCV2 stocks were diluted to
2.5×105 PFU/ml, and ﬁve pigs in each group were inoculated with a
2 ml volume of the appropriate virus by the intramuscular route. After
inoculation, an aliquot of each inoculum was back-titrated by plaque
assay to conﬁrm the titer of virus. Pigs were monitored for general
condition, depression, appetite, coughing, sneezing, and respiratory
distress on a daily basis. Rectal temperatures were measured daily for
the ﬁrst week. Pigs received a second inoculation of the same virus on
day 21. All pigs were weighed upon arrival at the site and at necropsy
on day 35. Blood samples were collected on days 0, 4, 7, 10, 14, 21, 28
and 35 for virus isolation and serology. Serum samples were aliquoted
and stored immediately at −80 °C until assayed. The pigs were
euthanized on day 35 and tonsil samples were collected for evaluation
of viral RNA via RT-PCR. Research personnel evaluating clinical
parameters and performing assays were blind to the infection status
of the pigs until after scoring and assays were completed. The study
protocol was approved by the University of Guelph Animal Care
Committee.
ELISA
Antibody titers for PRRSV were determined by the Animal Health
Laboratory of the University of Guelph, using a commercially available
PRRS antibody detection kit according to the manufacturer's instruc-
tions (HerdCheck PRRS; IDEXX, Westbrook, Maine). ELISA results
were expressed as a ratio of the optical density of the sample com-
pared to the optical density of the positive control (S/P ratio). A S/P
99Y. Pei et al. / Virology 389 (2009) 91–99ratio greater than 0.4 was considered positive for the presence of
PRRSV antibodies.
For PCV2 and GFP ELISAs, puriﬁed PCV2 virions and GFP protein
(Sigma) were coated onto 96-well microtiter plates and incubated
overnight at 4 °C in 50mMcarbonate/bicarbonate buffer (pH9.6). Plates
were washed 5 times with water and blocked with PBS containing 3%
heat-inactivatedhorse serumfor 30min. Theplateswere then incubated
for 2 h with 100 μl/well of serum samples diluted 1:20 in PBST (10 mM
PBS with 0.05% Tween-20) containing 1% horse serum. Following 4
washes, the plates were incubated for 1 h with alkaline phosphatase-
conjugated rabbit anti-swine IgG (H and L) (KPL) at a dilution of 1:2000
in PBST containing 1% horse serum. The plate was washed again with
PBST 4 times and incubated with BCIP and NBT staining solution
(BioRad) at 37 °C for 15 min. Reactions were stopped with 0.1 M EDTA
and optical density was measured by spectrometry at 450 nm.
Acknowledgments
This study was supported by the National Pork Board and the
National Research Initiatives of the US Department of Agriculture
Cooperative State Research Education and Extension Service, grant
numbers 2004-35605-14197 and 2008-35204-04634.
References
Albina, E., 1997. Epidemiology of porcine reproductive and respiratory syndrome
(PRRS): an overview. Vet. Microbiol. 55, 309–316.
Benﬁeld, D.A., Nelson, E., Collins, J.E., Harris, L., Goyal, S.M., Robison, D., Christianson,
W.T., Morrison, R.B., Gorcyca, D., Chladek, D., 1992. Characterization of swine
infertility and respiratory syndrome (SIRS) virus (isolate ATCC VR-2332). J. Vet.
Diagn. Invest. 4, 127–133.
Chae, C., 2005. A review of porcine circovirus 2-associated syndromes and diseases. Vet.
J. 169, 326–336.
Charerntantanakul, W., Platt, R., Roth, J.A., 2006. Effects of porcine reproductive and
respiratory syndrome virus-infected antigen-presenting cells on T cell activation
and antiviral cytokine production. Viral Immunol. 19, 646–661.
de Vries, A.A., Chirnside, E.D., Bredenbeek, P.J., Gravestein, L.A., Horzinek, M.C., Spaan,
W.J., 1990. All subgenomicmRNAs of equine arteritis virus contain a common leader
sequence. Nucleic Acids Res. 18, 3241–3247.
de Vries, A.A., Glaser, A.L., Raamsman, M.J., de Haan, C.A., Sarnataro, S., Godeke, G.J.,
Rottier, P.J., 2000. Genetic manipulation of equine arteritis virus using full-length
cDNA clones: separation of overlapping genes and expression of a foreign epitope.
Virology 270, 84–97.
den Boon, J.A., Kleijnen, M.F., Spaan, W.J., Snijder, E.J., 1996. Equine arteritis virus
subgenomic mRNA synthesis: analysis of leader-body junctions and replicative-
form RNAs. J. Virol. 70, 4291–4298.
den Boon, J.A., Snijder, E.J., Chirnside, E.D., de Vries, A.A., Horzinek, M.C., Spaan, W.J.,
1991. Equine arteritis virus is not a togavirus but belongs to the coronaviruslike
superfamily. J. Virol. 65, 2910–2920.
Fang, Y., Rowland, R.R., Roof, M., Lunney, J.K., Christopher-Hennings, J., Nelson, E.A.,
2006. A full-length cDNA infectious clone of North American type 1 porcine
reproductive and respiratory syndrome virus: expression of green ﬂuorescent
protein in the Nsp2 region. J. Virol. 1144 (7–1), 80 1455.
Fenaux, M., Halbur, P.G., Gill, M., Toth, T.E., Meng, X.J., 2000. Genetic characterization of
type 2 porcine circovirus (PCV-2) from pigs with postweaning multisystemic
wasting syndrome in different geographic regions of North America and deve-
lopment of a differential PCR-restriction fragment length polymorphism assay to
detect and differentiate between infections with PCV-1 and PCV-2. J. Clin.
Microbiol. 38, 2494–2503.
Fenaux, M., Opriessnig, T., Halbur, P.G., Elvinger, F., Meng, X.J., 2004. A chimeric porcine
circovirus (PCV) with the immunogenic capsid gene of the pathogenic PCV type 2
(PCV2) cloned into the genomic backbone of the nonpathogenic PCV1 induces
protective immunity against PCV2 infection in pigs. J. Virol. 78, 6297–6303.
Groot Bramel-Verheije, M.H., Rottier, P.J.M., Meulenberg, J.J.M., 2000. Expression of a
foreign epitope by porcine reproductive and respiratory syndrome virus. Virology
278, 380–389.
Han, J., Liu, G., Wang, Y., Faaberg, K.S., 2007. Identiﬁcation of nonessential regions of the
nsp2 replicase protein of porcine reproductive and respiratory syndrome virus
strain VR-2332 for replication in cell culture. J. Virol. 81, 9878–9890.
Harms, P.A., Sorden, S.D., Halbur, P.G., Bolin, S.R., Larger, K.M., Morozov, I., Paul, P.S., 2001.
Experimental reproduction of severe disease in CD/CD pigs concurrently infected
with type 2 porcine circovirus and porcine reproductive and respiratory syndrome
virus. Vet. Pathol. 38, 528–539.Hasslung, F., Wallgren, P., Ladekjaer-Hansen, A.S., Bøtner, A., Nielsen, J., Wattrang, E.,
Allan, G.M., McNeilly, F., Ellis, J., Timmusk, S., Belák, K., Segall, T., Melin, L., Berg, M.,
Fossum, C., 2005. Experimental reproduction of postweaning multisystemic
wasting syndrome (PMWS) in pigs in Sweden and Denmark with a Swedish
isolate of porcine circovirus type 2. Vet Microbiol. 106, 49–60.
Keffaber, K.K., 1989. Reproductive failure of unknown etiology. Am. Assoc. Swine
Practitioners Newsletter 1, 1–9.
Kim, H.S., Kwang, J., Yoon, I.J., Joo, H.S., Frey, M.L., 1993. Enhanced replication of porcine
reproductive and respiratory syndrome (PRRS) virus in a homogeneous sub-
population of MA-104 cell line. Arch. Virol. 133, 477–483.
Kim, J., Chung, H.K., Chae, C., 2003. Association of porcine circovirus 2 with porcine
respiratory disease complex. Vet. J. 166, 251–256.
Kim, D.Y., Calvert, J.G., Chang, K.O., Horlen, K., Kerrigan, M., Rowland, R.R.R., 2007.
Expression and stability of foreign tags inserted into nsp2 of porcine reproductive
and respiratory syndrome virus (PRRSV). Virus Res. 128, 106–114.
Larochelle, R., Magar, R., D'Allaire, S., 2003. Comparative serologic and virologic study of
commercial swine herds with and without postweaning multisystemic wasting
syndrome. Can. J. Vet. Res. 67, 114–120.
Lee, C., Calvert, J.G.,Welch, S.W., Yoo, D., 2005. ADNA-launched reverse genetics system for
porcine reproductive and respiratory syndrome virus reveals that homodimerization
of the nucleocapsid protein is essential for virus infectivity. Virology 331, 47–62.
Lee, C., Hodgins, D., Calvert, J.G., Welch, S.K., Jolie, R., Yoo, D., 2006. Mutations within the
nuclear localization signal of the porcine reproductive and respiratory syndrome
virus nucleocapsid protein attenuate virus replication. Virology 346, 238–250.
Liu, Q., Tikoo, S.K., Babiuk, L.A., 2001. Nuclear localization of the ORF2 protein encoded
by porcine circovirus type 2. Virology 285, 91–99.
Magar, R., Müller, P., Larochelle, R., 2000. Retrospective serological survey of antibodies
to porcine circovirus type 1 and type 2. Can. J. Vet. Res. 64, 184–186.
Mankertz, A., Mankertz, J., Wolf, K., Buhk, H.J., 1998. Identiﬁcation of a protein essential
for replication of porcine circovirus. J. Gen. Virol. 79, 381–384.
Meng, X.J., Paul, P.S., Halbur, P.G., Lum,M.A.,1995. Phylogenetic analysis of the putativeM
(ORF 6) and N (ORF 7) genes of porcine reproductive and respiratory syndrome
virus (PRRSV): implication for the existence of two genotypes of PRRSV in theU. S. A.
and Europe. Arch. Virol. 140, 745–755.
Meulenberg, J.J., Hulst, M.M., de Meijer, E.J., Moonen, P.J.M., den Besten, A., De Kluyver,
E.P., Wensvoort, G., Moormann, R.J., 1993. Lelystad virus, the causative agent of
porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and
EAV. Virology 192, 62–72.
Meulenberg, J.J., Petersen-den Besten, A., De Kluyver, E.P., Moormann, R.J., Schaaper,
W.M., Wensvoort, G., 1995. Characterization of proteins encoded by ORFs 2 to 7 of
Lelystad virus. Virology 206, 155–163.
Nawagitgul, P., Morozov, I., Bolin, S.R., Harms, P.A., Sorden, S.D., Paul, P.S., 2000. Open
reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. J. Gen.
Virol. 81, 2281–2287.
Nelsen, C.J., Murtaugh, M.P., Faaberg, K.S., 1999. Porcine reproductive and respiratory syn-
drome virus comparison: divergent evolution on two continents. J. Virol. 73, 270–280.
Nelson, E.A., Christopher-Hennings, J., Drew,T.,Wensvoort,G., Collins, J.E., Benﬁeld,D.A.,1993.
Differentiation of US and European isolates of porcine reproductive and respiratory
syndrome virus by monoclonal antibodies. J. Clin. Microbiol. 31, 3184–3189.
Pasternak, A.O., Gultyaev, A.P., Spaan, W.J.M., Snijder, E.J., 2000. Genetic manipulation of
arterivirus alternative mRNA leader-body junction sites reveals tight regulation of
structural protein expression. J. Virol. 74, 11642–11653.
Pei, Y., Hodgins, D.C., Lee, C., Calvert, J.G., Welch, S.W., Jolie, R., Keith, M., Yoo, D., 2008.
Functional mapping of the porcine reproductive and respiratory syndrome (PRRS)
virus capsid protein nuclear localization signal and its pathogenic association. Virus
Res. 135, 107–114.
Rodríguez-Arrioja, G.M., Segalés, J., Calsamiglia, M., Resendes, A.R., Balasch, M., Plana-
Duran, J., Casal, J., Domingo, M., 2002. Dynamics of porcine circovirus type 2
infection in aherdof pigswith postweaningmultisystemicwasting syndrome. Am. J.
Vet. Res. 63, 354–357.
Sagripanti, J.L., Zandomeni, R.O., Weinmann, R., 1986. The cap structure of simian
hemorrhagic fever virion RNA. Virology 151, 146–150.
Sambrook, J., Russell, D.W., 2001. Molecular Cloning: a Laboratory Manual, 3rd ed. Cold
Spring Harbor, NY, Cold Spring Harbor Laboratory.
Snijder, E.J., Meulenberg, J.J., 1998. The molecular biology of arteriviruses. J. Gen. Virol.
79, 961–979.
van Dinten, L.C., Rensen, S., Gorbalenya, A.E., Snijder, E.J., 1999. Proteolytic processing of
the open reading frame 1b-encoded part of arterivirus replicase is mediated by
nsp4 serine protease and is essential for virus replication. J. Virol. 73, 2027–2033.
van Marle, G., van Dinten, L.C., Spaan, W.J., Luytjes, W., Snijder, E.J., 1999. Characteriza-
tion of an equine arteritis virus replicase mutant defective in subgenomic mRNA
synthesis. J. Virol. 73, 5274–5281.
Wills, R.W., Zimmerman, J.J., Yoon, K.J., Swenson, S.L., McGinley, M.J., Hill, H.T., Platt, K.B.,
Christopher-Hennings, J., Nelson, E.A., 1997. Porcine reproductive and respiratory
syndrome virus: a persistent infection. Vet. Microbiol. 55, 231–240.
Wootton, S.K., Yoo, D., Rogan, D., 2000. Full-length sequence of a Canadian porcine
reproductive and respiratory syndrome virus (PRRSV) isolate. Arch. Virol. 145,
2297–2323.
Yoo, D., Welch, S.K., Lee, C., Calvert, J.G., 2004. Infectious cDNA clones of porcine
reproductive and respiratory syndrome virus and their potential as vaccine vectors.
Vet. Immunol. Immunopathol. 102, 143–154.
